Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
8.05
+0.06 (0.75%)
Mar 6, 2026, 11:25 AM CST

Merdury Biopharmaceutical Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
3,3435,4987,7784,006--
Market Cap Growth
-51.17%-29.32%94.15%---
Enterprise Value
3,1915,2757,4653,937--
Last Close Price
7.9913.0518.709.87--
PS Ratio
13590.931107.827530.001494.92--
PB Ratio
13.2518.9420.0322.22--
P/TBV Ratio
13.5319.2420.1722.28--
EV/Sales Ratio
-1062.907226.331469.06--
Debt / Equity Ratio
0.190.160.110.240.19-1.43
Net Debt / Equity Ratio
-0.60-0.63-0.74-0.54-0.05-1.02
Net Debt / EBITDA Ratio
2.383.936.893.340.12-
Net Debt / FCF Ratio
2.564.105.211.030.05-0.99
Asset Turnover
0.000.010.000.02--
Quick Ratio
9.0212.0340.8919.791.500.28
Current Ratio
9.2112.6342.2120.152.300.32
Return on Equity (ROE)
-24.50%-14.90%-15.41%-32.76%-103.62%-
Return on Assets (ROA)
-13.11%-8.54%-8.55%-15.87%-49.15%-103.35%
Return on Capital Employed (ROCE)
-24.80%-16.20%-10.60%-13.90%-45.40%100.50%
Earnings Yield
-2.11%-0.92%-0.56%-0.78%--
FCF Yield
-1.78%-0.81%-0.71%-2.35%--
Buyback Yield / Dilution
-4.65%-5.79%-5.83%-36.09%-165.94%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.